Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) [Phase 2]

View source ↗

Summary

A Phase 2 study of SAR441344 in primary Sjögren's syndrome completed, with safety, tolerability, pharmacokinetics, and preliminary efficacy results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• SAR441344

Snippet

Sponsor: Sanofi | Conditions: Sjögren's Syndrome, Sjogren's Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-10-09